Leggett & Platt is caught in an uncomfortable squeeze between a short position that refuses to budge and options traders who just turned more defensive than at any point in recent memory.
The options market is flashing the clearest near-term signal. The put/call ratio has climbed to 0.63 — more than two standard deviations above its 20-day mean of 0.51 — making this the most defensive options posture in months. That jump from a baseline where call volume dominated to a noticeably put-heavy skew has happened fast: as recently as mid-August the ratio was sitting comfortably inside its normal range. Something shifted this week, and it coincides with a stock that has shed 16.5% over the past month to trade at $9.32.
Short interest tells a story of entrenched conviction, not fresh aggression. At 16.5% of free float, the short position is substantial — up roughly 7% over the past month — but the weekly move is effectively flat, up less than 0.02%. That steadiness suggests existing shorts are holding rather than pressing. The borrow market does nothing to discourage them: cost to borrow is a negligible 0.49%, down nearly 9% on the week and 28% over the past month. With availability running at around 1,236% — meaning there are more than twelve times as many shares available to lend as are currently borrowed — the lending pool is entirely unconstrained. Shorts face no friction here. The ORTEX short score has edged up to 62.5, creeping higher every session this week, a reading that places LEG among the more shorted names in the market by ORTEX's composite measure.
The Street offers little by way of a bull thesis at current levels. Both active coverage names — Piper Sandler and Truist — cut their targets following the August earnings release, to $10 and $11 respectively, both maintaining neutral or hold ratings. With the stock at $9.32, the consensus mean target of $10.50 implies only about 13% upside — slim reward for a name carrying this much short interest. The bear case centers on the Bedding Products segment, where volumes fell 10% year-over-year in the most recent quarter, compounded by retailer merchandising shifts affecting key accounts. The bull case leans on margin progress — adjusted EBITDA margins expanded by 210 basis points — and improving sequential bedding trends. On valuation, the stock trades at roughly 11x trailing earnings with an EV/EBITDA of 8.5x, multiples that look cheap in isolation but have not attracted meaningful buying pressure.
The institutional flow picture adds one interesting wrinkle. FMR added over 6.4 million shares in the most recent reporting period, making it the second-largest holder at 12.3% of shares. Goldman Sachs also built a new position of nearly 6.7 million shares. Against that, Vanguard trimmed by over 3.7 million shares. The net picture is mixed — passive flows in, some active accumulation, but no single buyer large enough to shift the narrative on a stock where short interest runs at nearly the same level as BlackRock's entire position.
The next scheduled catalyst is the Q3 earnings release on November 6. The two most recent prints produced opposite reactions — a 2.5% gain on the August 13 announcement but a 6.1% drop on August 6 — and the five-day drift after that August 6 print extended the loss to 5.4%. With options positioning now the most defensively skewed in months and shorts sitting tight at elevated levels, the November print becomes the next meaningful test of whether margin improvement can outrun volume headwinds in the Bedding segment.
See the live data behind this article on ORTEX.
Open LEG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
